Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 9 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Author(s): Alexander Fanaroff Added: 1 year ago
ACC.24 — Dr Alexander Fanaroff (Penn Medicine, US) joins us onsite at ACC.24 to discuss the findings from the BE ACTIVE study, which investigated behavioural economic approaches to increasing physical activity (PA) in patients with an elevated risk of cardiovascular disease (NCT03911141).This randomized, controlled trial enrolled 1062 patients with a 10-year atherosclerotic cardiovascular risk… View more

Prevention & Chronic Conditions
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 1 month ago

Guidelines & Statements
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Joshua Stolker , Philippe Gabriel Steg , Roberta Rossini , et al Added: 8 months ago

COVID-19

MI/ACS
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 9 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Naveed Sattar , Philippe Gabriel Steg , Lale Tokgözoğlu , et al Added: 1 year ago
Watch this on-demand programme chaired by Prof Naveed Sattar (School of Cardiovascular and Metabolic Health, Glasgow, UK). Radcliffe Cardiology presents a distinguished panel of experts: Prof Gabriel Steg (University Institute of France, Paris, FR), Prof Lale Tokgozoglu (Hacettepe University, Ankara, TR), and Dr Joshua Stolker (St Louis Hospital, Missouri, US). This roundtable discussion explores… View more

Anticoagulation
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 10 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 1 year ago

Prevention & Chronic Conditions